Compare Ginkgo Bioworks Holdings Inc (DNA) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Symbotic Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.09 (market cap $763.64M), while Symbotic Inc trades at $42.5 (market cap $5.46B). The key difference: Symbotic Inc is far larger — about 7.1× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Symbotic Inc for 23 Days on average.
| DNA | SYM | |
|---|---|---|
Market Cap | $763.64M | $5.46B |
Volume | 3,204,177 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $15.83 | $87.30 |
52-Week Low | $5.48 | $38.22 |
Typical Hold Time | 7 Days | 23 Days |
Enterprise Value | $865.59M | $3.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
SYM trades at $43.31, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported negative net income of -$16.94M for 2025 despite $2.25B revenue, though 2026 projections show improvement to $8M net profit. Analysts maintain a buy consensus with a $60.33 price target, representing 39% upside potential from current levels.
SYM presents growth potential with a massive $22.5B backlog and expanding robotics/AI market, but faces significant customer concentration risk (85% revenue from Walmart) and recent earnings misses. The stock appears undervalued with a P/E of 1.05, though high EV/EBITDA of 74.05 suggests premium valuation relative to current earnings power.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
